INTERNATIONAL PATENT: NATIONAL CANCER CENTER, 国立研究開発法人国立がん研究センター, TAKARA BIO INC., タカラバイオ株式会社 FILES APPLICATION FOR "PEPTIDE-SPECIFIC TCR DERIVED FROM HLA-A02-RESTRICTED GLYPICAN-3"

Posted On: 2025-06-03

GENEVA, June 3 -- NATIONAL CANCER CENTER (1-1, Tsukiji 5-chome, Chuo-ku, Tokyo1040045), 国立研究開発法人国立がん研究センター (東京都中央区築地五丁目１番１号), TAKARA BIO INC. (4-38, Nojihigashi 7-chome, Kusatsu-shi, Shiga5250058), タカラバイオ株式会社 (滋賀県草津市野路東七丁目４番３８号) filed a patent application (PCT/JP2024/041158) for "PEPTIDE-SPECIFIC TCR DERIVED FROM HLA-A02-RESTRIC...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: NATIONAL CANCER CENTER, 国立研究開発法人国立がん研究センター, TAKARA BIO INC., タカラバイオ株式会社 FILES APPLICATION FOR "PEPTIDE-SPECIFIC TCR DERIVED FROM HLA-A02-RESTRICTED GLYPICAN-3"